These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27637151)

  • 1. Discovery of novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 1.
    Tsuno N; Yukimasa A; Yoshida O; Ichihashi Y; Inoue T; Ueno T; Yamaguchi H; Matsuda H; Funaki S; Yamanada N; Tanimura M; Nagamatsu D; Nishimura Y; Ito T; Soga M; Horita N; Yamamoto M; Hinata M; Imai M; Morioka Y; Kanemasa T; Sakaguchi G; Iso Y
    Bioorg Med Chem Lett; 2016 Oct; 26(20):4930-4935. PubMed ID: 27637151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 2.
    Tsuno N; Yukimasa A; Yoshida O; Suzuki S; Nakai H; Ogawa T; Fujiu M; Takaya K; Nozu A; Yamaguchi H; Matsuda H; Funaki S; Nishimura Y; Ito T; Nagamatsu D; Asaki T; Horita N; Yamamoto M; Hinata M; Soga M; Imai M; Morioka Y; Kanemasa T; Sakaguchi G; Iso Y
    Bioorg Med Chem Lett; 2016 Oct; 26(20):4936-4941. PubMed ID: 27634196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological evaluation of novel (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives as TRPV4 antagonists for the treatment of pain.
    Tsuno N; Yukimasa A; Yoshida O; Suzuki S; Nakai H; Ogawa T; Fujiu M; Takaya K; Nozu A; Yamaguchi H; Matsuda H; Funaki S; Yamanada N; Tanimura M; Nagamatsu D; Asaki T; Horita N; Yamamoto M; Hinata M; Soga M; Imai M; Morioka Y; Kanemasa T; Sakaguchi G; Iso Y
    Bioorg Med Chem; 2017 Apr; 25(7):2177-2190. PubMed ID: 28284871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of orally-bioavailable antagonists of the TRPV4 ion-channel.
    Wei ZL; Nguyen MT; O'Mahony DJ; Acevedo A; Zipfel S; Zhang Q; Liu L; Dourado M; Chi C; Yip V; DeFalco J; Gustafson A; Emerling DE; Kelly MG; Kincaid J; Vincent F; Duncton MA
    Bioorg Med Chem Lett; 2015 Sep; 25(18):4011-5. PubMed ID: 26235950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
    Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
    J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
    Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
    J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4).
    Brnardic EJ; Ye G; Brooks C; Donatelli C; Barton L; McAtee J; Sanchez RM; Shu A; Erhard K; Terrell L; Graczyk-Millbrandt G; He Y; Costell MH; Behm DJ; Roethke T; Stoy P; Holt DA; Lawhorn BG
    J Med Chem; 2018 Nov; 61(21):9738-9755. PubMed ID: 30335378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
    Voight EA; Gomtsyan AR; Daanen JF; Perner RJ; Schmidt RG; Bayburt EK; DiDomenico S; McDonald HA; Puttfarcken PS; Chen J; Neelands TR; Bianchi BR; Han P; Reilly RM; Franklin PH; Segreti JA; Nelson RA; Su Z; King AJ; Polakowski JS; Baker SJ; Gauvin DM; Lewis LR; Mikusa JP; Joshi SK; Faltynek CR; Kym PR; Kort ME
    J Med Chem; 2014 Sep; 57(17):7412-24. PubMed ID: 25100568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
    Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
    J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Brown BS; Keddy R; Zheng GZ; Schmidt RG; Koenig JR; McDonald HA; Bianchi BR; Honore P; Jarvis MF; Surowy CS; Polakowski JS; Marsh KC; Faltynek CR; Lee CH
    Bioorg Med Chem; 2008 Sep; 16(18):8516-25. PubMed ID: 18722778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
    Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
    J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
    Wang HL; Katon J; Balan C; Bannon AW; Bernard C; Doherty EM; Dominguez C; Gavva NR; Gore V; Ma V; Nishimura N; Surapaneni S; Tang P; Tamir R; Thiel O; Treanor JJ; Norman MH
    J Med Chem; 2007 Jul; 50(15):3528-39. PubMed ID: 17585751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
    García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
    J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
    Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRPV4 agonists and antagonists.
    Vincent F; Duncton MA
    Curr Top Med Chem; 2011; 11(17):2216-26. PubMed ID: 21671873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
    Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
    J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
    Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):1857-72. PubMed ID: 15771431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation of peripheral TRPV1, TRPV4, TRPA1 and ASIC in a magnesium sulfate-induced local pain model in rat.
    Srebro D; Vučković S; Prostran M
    Neuroscience; 2016 Dec; 339():1-11. PubMed ID: 27687800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain management.
    Tafesse L; Kanemasa T; Kurose N; Yu J; Asaki T; Wu G; Iwamoto Y; Yamaguchi Y; Ni C; Engel J; Tsuno N; Patel A; Zhou X; Shintani T; Brown K; Hasegawa T; Shet M; Iso Y; Kato A; Kyle DJ
    J Med Chem; 2014 Aug; 57(15):6781-94. PubMed ID: 25057800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of N
    Gao M; Nie C; Li J; Song B; Cheng X; Sun E; Yan L; Qian H
    Bioorg Chem; 2019 Feb; 82():100-108. PubMed ID: 30278281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.